Jiangsu Hengrui Pharmaceuticals (SHA:600276) subsidiaries obtained clinical trial approval from China's drug regulator for cancer drugs SHR-3821, adebrelimab and rilafusp α.
The approved trial is a Phase Ib/II study combining SHR-3821 with other therapies for solid tumors, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 2% in recent trade.
Globtier lnfotec's (BOM:544494) confirmed the formal departure of its Chief Financial Officer, Sandeep Gupta, effective May 13, according to a same-day filing on BSE.Shares of the company fell 5% in Thursday's trade.Gupta had resigned in April to pursue opportunities outside the company.
Australian shares were flat with positive bias on Thursday as the summit between the US and Chinese Presidents gets underway.The S&P/ASX 200 Index was little changed to close at 8,640.70.US President Donald Trump and Chinese counterpart Xi Jinping met in Beijing. Brent crude oil futures were trading around $105.89 per barrel. Gold fell as the hotter-than-expected US inflation data increased the chances of a tighter monetary policy in the US.On the domestic front, Australia's household spending fell 1.2% in April, reversing a fuel-driven surge in March as lower spending on petrol and public transport weighed on transport and recreation spending, according to the Commonwealth Bank of Australia's Household Spending Insights."The oil shock resulting from the current Middle East conflict has not had the size of impact that was initially expected," the bank's head of Australian Economics, Belinda Allen, said.In company news, Australia's Federal Court ruled Thursday that Coles Group (ASX:COL) deceived shoppers by advertising discounts on products that, in many cases, were being sold at higher prices. The case against Coles was brought by the Australian Competition and Consumer Commission (ACCC) in 2024, saying Coles increased prices on certain items for a very short period of time before putting them on a discount, making the promotions illusory in nature. Its shares fell 2% on market close.Xero (ASX:XRO) reported Thursday that it swung to a loss of NZ$0.19 per share in the fiscal year 2026 from a profit of NZ$1.47 a year earlier. Total operating revenue for the 12 months ended March 31 was NZ$2.75 billion, compared with NZ$2.1 billion a year earlier. Its shares closed down 9%.Lastly, Megaport (ASX:MP1) said its unit Latitude.sh has secured three major GPU, CPU, network, and storage contracts with a combined total contract value (TCV) of about AU$254 million and annualized recurring revenue (ARR) of about AU$90.6 million. Its shares were up 28% on market close.
HFCL (NSE:HFCL, BOM:500183) has received board approval to establish a defense manufacturing facility in Andhra Pradesh, India with an initial outlay of 2.30 billion Indian rupees, according to a Thursday filing to the Indian stock exchages.The proposed facility be used to design, develop and manufacture multi-mode hand grenades and similar other products and advanced defense systems.The facility is expected to be completed by December 2027 and it is estimated to add capacity of 4 million units.The company's shares were down over 4% in recent trade.